[
    [
        {
            "time": "",
            "original_text": "建议关注医药国改机会，港股医药配置价值凸显｜【光大医药·周报】",
            "features": {
                "keywords": [
                    "医药",
                    "国改",
                    "港股",
                    "配置价值"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "建议关注医药国改机会，港股医药配置价值凸显｜【光大医药·周报】",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "汇丰：升上海医药(02607.HK)目标价至23.7港元评级“买入”",
            "features": {
                "keywords": [
                    "汇丰",
                    "上海医药",
                    "目标价",
                    "买入"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "汇丰：升上海医药(02607.HK)目标价至23.7港元评级“买入”",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【公司追踪】上海医药 (601607)丨收入增速回暖，利润有望反弹",
            "features": {
                "keywords": [
                    "上海医药",
                    "收入增速",
                    "利润",
                    "反弹"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【公司追踪】上海医药 (601607)丨收入增速回暖，利润有望反弹",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "继伦敦AIM和纳斯达克之后，李嘉诚投资的这家药企要再冲刺港交所！",
            "features": {
                "keywords": [
                    "李嘉诚",
                    "药企",
                    "港交所",
                    "投资"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "继伦敦AIM和纳斯达克之后，李嘉诚投资的这家药企要再冲刺港交所！",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]